Abstract
The hemagglutinin-tagged human trace amine-associated receptor1 (TAAR1) was stably coexpressed with rat Gαs in the AV12-664 cell line, and receptor activation was measured as the stimulation of cAMP formation. After blockade of endogenously expressed α2- and β-adrenoceptors with 2-[2-(2-methoxy-1,4-benzodioxanyl)]-imidazoline hydrochloride (2-methoxyidazoxan, RX821002) and alprenolol, respectively, the resulting pharmacology was consistent with that of a unique receptor subtype. β-Phenylethylamine (β-PEA), the putative endogenous ligand, gave an EC50 of 106 ± 5 nM in the assay. For a series of β-PEA analogs used to explore the pharmacophore, small substituents at ring positions 3 and/or 4 generally resulted in compounds having lower potency than β-PEA, although several were as potent as β-PEA. However, small substituents at ring position 2 resulted in a number of compounds having potencies as good as or better than β-PEA. A number of nonselective antagonists known to share affinity for multiple monoaminergic receptors were evaluated for their ability to inhibit β-PEA stimulation of the human TAAR1. None had an IC50 <10 μM. For comparison, the rat TAAR1 receptor was expressed in the AV12-664 cell line. A number of agonist compounds had significantly different relative potencies between the rat and human TAAR1, demonstrating a significant species difference between the rat and human TAAR1. The TAAR1 receptor exhibits a pharmacologic profile uniquely different from those of classic monoaminergic receptors, consistent with the structural information that places them in a distinct family of receptors. This unique pharmacologic profile suggests the potential for development of TAAR-selective agonists and antagonists to study their physiologic roles.
Footnotes
-
This work was funded by Eli Lilly and Company.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.106.112532.
-
ABBREVIATIONS: TAAR1, trace amine-associated receptor 1; β-PEA, β-phenylethylamine; PCR, polymerase chain reaction; h, human; HA, hemagglutinin; r, rat; RX821002, 2-methoxyidazoxan, 2-[2-(2-methoxy-1,4-benzodioxanyl)]-imidazoline hydrochloride; Emax, maximal response of the compound relative to the maximal response produced by β-PEA.
- Received August 21, 2006.
- Accepted October 11, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|